Gastrointestinal Cancer Case Presentations (December 2, 2024)

This Gastrointestinal Tumor Board session will take place on December 2, 2024 at 7:00 a.m. Attendance is restricted to tumor board participants and will not be broadcast.

Activity Information

Needs Statement

Gastroenterologists, hepatologists, medical oncologists, surgical oncologists, thoracic surgeons, radiologists, pathologists, radiation oncologists, physician assistants, nurse practitioners, fellows, residents, and medical students need to receive regular updates on advances in the surgical and radiotherapeutic management of gastrointestinal cancer. The tumor board aims to advance the knowledge of learners regarding the fundamentals of tumor biology and the effects of tumor biology on treatment decisions. The tumor board also aims to promote a collaborative approach to complex cancer care, enhance the quality of gastrointestinal cancer care, and improve patient outcomes.

Educational Objectives

At the conclusion of the sessions, the participants should be able to:

  • Recognize the complexity of gastrointestinal oncologic care and the need for a multi-specialty team.
  • Describe the central role tumor boards play in devising, coordinating, and executing complex oncologic care plans.
  • Demonstrate greater understanding of the fundamentals of tumor biology and of how tumor biology factors into medical decision-making.
  • Identify barriers to patient involvement in clinical trials and ways to overcome them.

Target Audience

Professional Categories

  • Physicians
  • Medical Students
  • Fellows
  • Residents
  • Nurses
  • Other Health Professionals

Specialties

  • Gastroenterology and Hepatology
  • Oncology

Interest Groups

  • Hospital Medicine

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Social Work: The Baylor College of Medicine Division of Continuing Professional Development (License Number 7270) is an approved continuing education provider for Social Workers through the Texas State Board of Social Worker Examiners. This activity has been approved for 1 continuing education unit.

Maintenance of Certification (MOC) Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Part II MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to Accreditation Council for Continuing Medical Education (ACCME) for the purpose of granting ABIM MOC credit.

By signing in, you give Baylor College of Medicine permission to share your participation information/completion data with the specialty board referenced above through the ACCME Program and Activity Reporting System (PARS). Your MOC credit equates to the number of CME credits claimed for the activity and pending completion of the post-test with a minimum passing score of 70%. You can access your MOC credit(s) through the ABIM website at www.abim.org.

Activity Director

  1. Benjamin Leon Musher, M.D.

    Benjamin Leon Musher, M.D.

    Associate Professor
    Baylor College of Medicine

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:

Presenter

  1. Benjamin Leon Musher, M.D.

    Benjamin Leon Musher, M.D.

    Associate Professor
    Baylor College of Medicine

    Disclosure:
    • Research Support: Merck
    • Consultancy: Arimex; Gnubiotics

Activity Director

  1. Benjamin Leon Musher, M.D.

    Benjamin Leon Musher, M.D.

    Associate Professor
    Baylor College of Medicine

    Disclosure:
    • Research Support: Merck
    • Consultancy: Arimex; Gnubiotics

Planning Committee Members

  1. Tannaz Armaghany, M.D.

    Tannaz Armaghany, M.D.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

  2. Ernest Ramsay Camp, M.D., FACS

    Ernest Ramsay Camp, M.D., FACS

    Olga Keith Wiess Chair of Surgery
    Baylor College of Medicine

    Disclosure:
    • Research Support: Merck
  3. Shalini Makawita, M.D., M.Sc.

    Shalini Makawita, M.D., M.Sc.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

  4. Benjamin Leon Musher, M.D.

    Benjamin Leon Musher, M.D.

    Associate Professor
    Baylor College of Medicine

    Disclosure:
    • Research Support: Merck
    • Consultancy: Arimex; Gnubiotics
  5. George Van Buren, II, M.D., FACS

    George Van Buren, II, M.D., FACS

    Associate Professor of Surgery
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

Presenter:

Benjamin Leon Musher, M.D.

Benjamin Leon Musher, M.D.

Associate Professor Baylor College of Medicine

Health Topics

You May Also Be Interested In

Upcoming
Head, Neck, and Thyroid Cancer Multidisciplinary Treatment Planning Series
Activity duration: 1 hr
Credit 1.00 Continuing Medical Education Credits Available
Upcoming
Gastrointestinal Tumor Board
Activity duration: 1 hr
Credit 1.00 Continuing Medical Education Credits Available
Upcoming
Gastrointestinal Tumor Board
Activity duration: 1 hr
Credit 1.00 Continuing Medical Education Credits Available